WO2003046172A3 - Alzheimer’s disease model - Google Patents
Alzheimer’s disease model Download PDFInfo
- Publication number
- WO2003046172A3 WO2003046172A3 PCT/GB2002/003229 GB0203229W WO03046172A3 WO 2003046172 A3 WO2003046172 A3 WO 2003046172A3 GB 0203229 W GB0203229 W GB 0203229W WO 03046172 A3 WO03046172 A3 WO 03046172A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alzheimer
- functional equivalent
- transgenic non
- heterologous polynucleotide
- human animal
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 230000009261 transgenic effect Effects 0.000 abstract 2
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 abstract 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 210000004958 brain cell Anatomy 0.000 abstract 1
- 210000004898 n-terminal fragment Anatomy 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002364885A AU2002364885A1 (en) | 2001-11-09 | 2002-07-12 | Alzheimer's disease model |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0126988.5 | 2001-11-09 | ||
GBGB0126988.5A GB0126988D0 (en) | 2001-11-09 | 2001-11-09 | Disease model |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003046172A2 WO2003046172A2 (en) | 2003-06-05 |
WO2003046172A3 true WO2003046172A3 (en) | 2003-07-17 |
Family
ID=9925513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/003229 WO2003046172A2 (en) | 2001-11-09 | 2002-07-12 | Alzheimer’s disease model |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002364885A1 (en) |
GB (1) | GB0126988D0 (en) |
WO (1) | WO2003046172A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060153772A1 (en) * | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
US9439922B2 (en) | 2008-05-14 | 2016-09-13 | Jawaharlal Nehru Centre For Advanced Scientific Research | Tat DNA sequences, gene constructs, vaccine and processes thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1026251A2 (en) * | 1999-02-03 | 2000-08-09 | Pfizer Products Inc. | Transgenic animals expressing human P25 |
WO2001002552A2 (en) * | 1999-07-02 | 2001-01-11 | Janssen Pharmaceutica N.V. | Double transgenic animals as models for neurodegenerative disease |
-
2001
- 2001-11-09 GB GBGB0126988.5A patent/GB0126988D0/en not_active Ceased
-
2002
- 2002-07-12 AU AU2002364885A patent/AU2002364885A1/en not_active Abandoned
- 2002-07-12 WO PCT/GB2002/003229 patent/WO2003046172A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1026251A2 (en) * | 1999-02-03 | 2000-08-09 | Pfizer Products Inc. | Transgenic animals expressing human P25 |
WO2001002552A2 (en) * | 1999-07-02 | 2001-01-11 | Janssen Pharmaceutica N.V. | Double transgenic animals as models for neurodegenerative disease |
Non-Patent Citations (6)
Title |
---|
AHLIJANIAN M ET AL: "Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 6, 14 March 2000 (2000-03-14), pages 2910 - 2915, XP002142078, ISSN: 0027-8424 * |
ANGELO M ET AL: "Modelling cognitive deficits associated with Alzheimer's disease.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, 31st Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 10-15, 2001, pages 1448, XP001109571, ISSN: 0190-5295 * |
FISCHER ANDRE ET AL: "Cyclin-dependent kinase 5 is required for associative learning.", JOURNAL OF NEUROSCIENCE, vol. 22, no. 9, 1 May 2002 (2002-05-01), May 1, 2002, pages 3700 - 3707, XP008012755, ISSN: 0270-6474 * |
GARDONI F ET AL: "alphaCaMKII binding to the C-terminal tail of NMDA receptor subunit NR2A and its modulation by autophosphorylation", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 456, no. 3, 13 August 1999 (1999-08-13), pages 394 - 398, XP004260104, ISSN: 0014-5793 * |
LI BING-SHENG ET AL: "Regulation of NMDA receptors by cyclin-dependent kinase-5.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 22, 23 October 2001 (2001-10-23), October 23, 2001, pages 12742 - 12747, XP002228182, ISSN: 0027-8424 * |
PATRICK GENTRY N ET AL: "Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 402, no. 6762, 9 December 1999 (1999-12-09), pages 615 - 622, XP002136732, ISSN: 0028-0836 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003046172A2 (en) | 2003-06-05 |
AU2002364885A1 (en) | 2003-06-10 |
AU2002364885A8 (en) | 2003-06-10 |
GB0126988D0 (en) | 2002-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004033619A3 (en) | Method for assembly of a polynucleotide encoding a target polypeptide | |
BR0311655A (en) | Improved method for preventing or reducing turbidity in beverages. | |
EP2123675A3 (en) | Human EPO mimentic hinge core mimetibodies, compositions, methods and uses | |
WO2004000997A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
DE60315847D1 (en) | VARIANTS OF THE HUMAN COAGULATION FACTOR VII | |
WO2005004814A3 (en) | Sirt1 and genetic disorders | |
WO2002057453A3 (en) | Polypetides and nucleic acids encoding same | |
WO2003046172A3 (en) | Alzheimer’s disease model | |
WO2001090155A3 (en) | Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses | |
WO2002098917A3 (en) | Human proteins and nucleic acids encoding same | |
DE60134430D1 (en) | METHOD FOR THE TREATMENT OF DISEASES RELATED TO APOE | |
WO2002016599A3 (en) | Proteins and nucleic acids encoding same | |
UA88779C2 (en) | Plants having increased yield, and method for obtaining thereof | |
IL174726A (en) | Nonhuman animal comprising transgenic nucleic acid sequence coding for mutant presenilin 1 protein | |
DE60125148D1 (en) | FCTRX SPECIFIED PROTEINS AND NUCLEIC ACID ENCODING THEREFOR | |
WO2003078572A3 (en) | Therapeutic polypeptides, nucleic acids encoding same and methods of use | |
WO2003022998A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2003040329A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2002099061A3 (en) | Method of treating alzheimer's disease with se-containing peptide | |
WO2003026566A3 (en) | Atlastin | |
WO2002026826A3 (en) | Proteins and nucleic acids encoding same | |
WO2001051518A3 (en) | Nucleic acids encoding human semaphorin proteins and use thereof | |
WO2002000826A3 (en) | A novel polypeptide, a human dna methylation protein and the polynucleotide encoding the polypeptide | |
WO2003085096A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2004089282A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |